Table 1.
Patient characteristics.
| Patient Parameters | Patient Data |
|---|---|
| Number of patients | 52 |
| Sex | |
| Women | 15 |
| Men | 37 |
| Median age (range) | 59.9 (29–65) |
| Type of recurrence | |
| Distant | 33 |
| Local | 2 |
| Distant and local | 16 |
| Location of primary lesion | |
| Peripheral (extremities) | 25 |
| Central (head and torso) | 8 |
| Unknown primary | 19 |
| BRAF status | |
| BRAF V600 | 28 |
| BRAF-wildtype | 21 |
| Unknown | 3 |
| Blood parameters | |
| HGB ≥12.5 g/dL | 35 |
| HGB <12.5 g/dL | 17 |
| MCV 80–95 fl | 39 |
| MCV >95 fl | 5 |
| MCV <80 fl | 8 |
| MCH 27–32 pg | 41 |
| MCH >32 pg | 3 |
| MCH <27 pg | 8 |
| MCHC 27–32 g/dL | 48 |
| MCHC >32 g/dL | 3 |
| MCHC <27 g/dL | 0 |
| PLT 150.000–450.000 | 48 |
| PLT >450.000 | 4 |
| PLT <150.000 | 0 |
| LDH ≤240 U/L | 27 |
| LDH 241–480 U/L | 16 |
| LDH >481 U/L | 3 |
| Unknown LDH | 6 |
| ALT ≤40 U/L | 49 |
| ALT 41–200 U/L | 3 |
| AST ≤40 U/L | 48 |
| AST 41–200 U/L | 4 |
| Level of invasion (Clark classification) | |
| I | 1 |
| II | 1 |
| III | 4 |
| IV | 24 |
| V | 14 |
| Metastases | |
| Lymph nodes | 38 |
| Lung | 30 |
| Brain | 18 |
| Skin and subcutaneous tissue | 18 |
| Liver | 16 |
| Bones | 10 |
| Other | 15 |
| Primary surgical treatment | 47 |
| First-line treatment | 52 |
| Anti-BRAF/MEK | 28 |
| Vemurafenib | 24 |
| Dabrafenib | 3 |
| Vemurafenib + cobimetinib | 1 |
| Anti-PD-1/anti-CTLA4 | 24 |
| Pembrolizumab | 10 |
| Ipilimumab | 10 |
| Nivolumab | 4 |
| Second-line treatment | 27 |
| Ipilimumab | 16 |
| Nivolumab | 6 |
| Pembrolizumab | 5 |
| Other treatment | |
| Palliative radiotherapy | 23 |
| Surgical treatment of metastases | 14 |
| Surgical treatment of local recurrence | 11 |
Abbreviations: HGB—Hemoglobin, MCV—Mean corpuscular volume, MCH—Mean corpuscular hemoglobin, MCHC—Mean cell hemoglobin concentration, PLT—Platelet, LDH—Lactate dehydrogenase, ALT—Alanine aminotransferase, AST—Aspartate aminotransferase.